The performance of companies tied to Sildenafil's history presents a intricate investment picture . While the initial boom generated substantial gains, generic alternatives have significantly eroded market share . Investing in associated pharmaceutical companies now requires a discerning assessment of proprietary protection , evolving healthcare ch